4.6. Analysis.
Comparison 4: Casirivimab/imdevimab compared to placebo to prevent COVID‐19 (postexposure prophylaxis), Outcome 6: Adverse events: all grade
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.